Novartis and US government reach agreement on lowering drug prices in the US
Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be…
Novartis and US government reach agreement on lowering drug prices in the US
Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be…
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem®…
Radiopharmaceuticals Market to Reach US$ 13.4 Billion by 2033
AstuteAnalytica India Pvt. Ltd. Surging multibillion dollar acquisitions and a pipeline of innovative therapies define the current landscape.…
One in four Indians faces silent genetic threat to heart health, shows study
In the Asia Pacific and Middle East region, two in three individuals (66%) skip routine heart tests, while…
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
 Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for…
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease Â
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…